Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €445.10 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 5:30 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

54, Rue La Boétie

Paris, 75008

France

Phone: 33 1 53 77 40 00

Fax: 33 1 53 77 42 96

This oral phosphoinositide- 3-kinase (PI3K) inhibitor is under evaluation in a Phase I study of the new formulation (Polymorphic Form E Tablet). SAR405838 is a potent inhibitor of the HDM2/P53 interaction. The inactivation of the p53 function is an almost universal feature of human cancer cells. The program is in Phase I with two ongoing studies. SAR408701 is an ADC that binds to CEACAM-5, a membrane glycoprotein originally identified as a surface marker on adenocarcinomas of the human gastrointestinal tract. The compound entered the Sanofi Phase I pipeline in 2014 with one ongoing study. SAR566658 is an ADC loaded with a maytansinoid derivative DM4 (huDS6-SPDB-DM4) targeting CA6. CA6 is a tumor specific epitope highly expressed on some solid tumors. The program is in Phase I with one ongoing study. Cardiovascular Diseases Praluent — alirocumab (SAR236553), developed in collaboration with Regeneron: positive results from Phase III studies with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were obtained in 2014. Fresolimumab (GZ402669) — TGF-ß antagonist in Phase II for the treatment of Focal Segmental Glomerulosclerosis (FSGS). Immune Mediated diseases and MS Main Products in Phase III Sarilumab (SAR153191), a monoclonal antibody against the Interleukin-6 Receptor (anti IL-6R mAb) derived from the company’s alliance with Regeneron, is in Phase III in adult patients with moderate to severe rheumatoid arthritis (RA). The SARIL-RA Phase III program evaluating two doses of sarilumab is underway with one completed (SARIL-RA-MOBILITY) and six ongoing clinical studies, such as SARIL-RA-TARGET, SARIL-RA-ASCERTAIN, SARIL-RA-EXTEND, SARIL-RA-MONARCH, SARIL-RA-ONE, and SARIL-RA-EASY. Dupilumab (SAR231893) is a monoclonal antibody against the Interleukin-4 alpha Receptor derived from the company’s alliance with Regeneron. Dupilumab modulates signaling of both IL 4 and IL 13 pathways. It is being developed in various indications, such as atopic dermatitis in Phase III, asthma with a Phase III start planned in 2015, nasal polyposis (Positive Phase IIa proof of concept study) and eosinophilic eosophagitis in Phase II. Atopic Dermatitis, the Phase III program consists of 2 identical 16-week monotherapy treatment trials (SOLO 1 & SOLO 2); a long-term treatment trial in combination with topical corticosteroids; and an open-label extension study of dupilumab in patients with atopic dermatitis. Asthma: A randomized, double-blind, placebo-controlled, dose-ranging study to evaluate dupilumab in patients with moderate to severe uncontrolled asthma is ongoing and anticipated to complete in May 2015. Nasal Polyposis: An evaluation of dupilumab in patients with bilateral nasal polyposis and chronic symptoms of sinusitis — randomized, bouble-blind, Phase II, placebo controlled, 2 arm study- has been completed and further activities are ongoing in preparation for the next stage of development. Eosinophilic Esophagitis: Phase II study of dupilumab in adult patients with active eosinophilic esophagitis — randomized, double-blind, parallel, placebo-controlled study to assess the efficacy, safety and tolerability of dupilumab in this population, is to be initiated. Main Products in Phase II Vatelizumab (SAR339658), a humanized monoclonal antibody directed at the Very Late Antigen 2 integrin receptor, is in-licensed from Glenmark Pharmaceuticals. The primary target indication is relapsing form of MS (RMS). A Phase IIA/B study in remitting relapsing MS patients to assess proof of concept and dose response started in 2014, enrolment is ongoing. SAR156597 (humanized bi-specific monoclonal antibody targeting the IL-4 and IL-13 cytokines) is in Phase IIA in the treatment of idiopathic pulmonary fibrosis. Main Products in Early Stage GZ402668 (GLD52), an IgG1 monoclonal antibody binding to CD52 a cell surface antigen present at high level on T ab B lymphocytes, entered Phase I. SAR113244 (anti-CXCR5), a humanized monoclonal antibody in Phase I for the treatment of Systemic lupus Erythematosus. A Phase 1B multiple ascending dose stud

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHPP:FP €445.10 EUR 0.00

RHPP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $69.95 USD +0.22
Amgen Inc $174.80 USD -0.79
Bayer AG €136.60 EUR +1.75
Medtronic PLC $77.77 USD -0.23
Novo Nordisk A/S kr407.70 DKK +0.70
View Industry Companies
 

Industry Analysis

RHPP

Industry Average

Valuation RHPP Industry Range
Price/Earnings 26.5x
Price/Sales 3.5x
Price/Book 2.2x
Price/Cash Flow 17.5x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-TITR PART10%87, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.